Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience.

Asmarats L, Perlman G, Praz F, Hensey M, Chrissoheris MP, Philippon F, Ofek H, Ye J, Puri R, Pibarot P, Attinger A, Moss R, Bédard E, Moschovitis A, Reineke D, Lauck S, Blanke P, Leipsic J, Spargias K, Windecker S, Webb JG, Rodés-Cabau J.

JACC Cardiovasc Interv. 2019 Aug 12;12(15):1438-1447. doi: 10.1016/j.jcin.2019.04.038.

PMID:
31395213
2.

A Sensorimotor Circuit in Mouse Cortex for Visual Flow Predictions.

Leinweber M, Ward DR, Sobczak JM, Attinger A, Keller GB.

Neuron. 2017 Dec 6;96(5):1204. doi: 10.1016/j.neuron.2017.11.009. No abstract available.

3.

A Sensorimotor Circuit in Mouse Cortex for Visual Flow Predictions.

Leinweber M, Ward DR, Sobczak JM, Attinger A, Keller GB.

Neuron. 2017 Sep 13;95(6):1420-1432.e5. doi: 10.1016/j.neuron.2017.08.036. Erratum in: Neuron. 2017 Dec 6;96(5):1204.

4.

Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation: 1-Year Clinical and Echocardiographic Results.

Perlman G, Praz F, Puri R, Ofek H, Ye J, Philippon F, Carrel T, Pibarot P, Attinger A, Htun NM, Dvir D, Moss R, Campelo-Parada F, Bédard E, Reineke D, Moschovitis A, Lauck S, Blanke P, Leipsic J, Windecker S, Rodés-Cabau J, Webb J.

JACC Cardiovasc Interv. 2017 Oct 9;10(19):1994-2003. doi: 10.1016/j.jcin.2017.06.036. Epub 2017 Aug 2.

5.

Visuomotor Coupling Shapes the Functional Development of Mouse Visual Cortex.

Attinger A, Wang B, Keller GB.

Cell. 2017 Jun 15;169(7):1291-1302.e14. doi: 10.1016/j.cell.2017.05.023. Epub 2017 Jun 9.

6.

The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells.

Murone M, Radpour R, Attinger A, Chessex AV, Huguenin AL, Schürch CM, Banz Y, Sengupta S, Aguet M, Rigotti S, Bachhav Y, Massière F, Ramachandra M, McAllister A, Riether C.

Mol Cancer Ther. 2017 Aug;16(8):1497-1510. doi: 10.1158/1535-7163.MCT-16-0889. Epub 2017 May 3.

7.

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.

Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, Bachhav Y, Brienza S, Traxler P, Lang M, Aguet M, Zoete V, Michielin O, Nicholas C, Johnson FM, Ramachandra M, McAllister A.

Mol Cancer Ther. 2016 Oct;15(10):2334-2343. Epub 2016 Jul 20.

8.

Transcriptional reprogramming of mature CD4⁺ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes.

Mucida D, Husain MM, Muroi S, van Wijk F, Shinnakasu R, Naoe Y, Reis BS, Huang Y, Lambolez F, Docherty M, Attinger A, Shui JW, Kim G, Lena CJ, Sakaguchi S, Miyamoto C, Wang P, Atarashi K, Park Y, Nakayama T, Honda K, Ellmeier W, Kronenberg M, Taniuchi I, Cheroutre H.

Nat Immunol. 2013 Mar;14(3):281-9. doi: 10.1038/ni.2523. Epub 2013 Jan 20.

9.

A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants.

Nahimana A, Aubry D, Lagopoulos L, Greaney P, Attinger A, Demotz S, Dawson KM, Schapira M, Tschopp J, Dupuis M, Duchosal MA.

Blood Cancer J. 2011 Dec;1(12):e47. doi: 10.1038/bcj.2011.47. Epub 2011 Dec 9.

10.

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.

Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjørnelund J, Dawson KM, Dupuis M, Duchosal MA.

Blood. 2009 Apr 2;113(14):3276-86. doi: 10.1182/blood-2008-08-173369. Epub 2009 Feb 5.

11.

Identification of pre- and postselection TCRalphabeta+ intraepithelial lymphocyte precursors in the thymus.

Gangadharan D, Lambolez F, Attinger A, Wang-Zhu Y, Sullivan BA, Cheroutre H.

Immunity. 2006 Oct;25(4):631-41.

12.

Feasibility of mobile cardiopulmonary exercise testing.

Attinger A, Tüller C, Souren T, Tamm M, Schindler C, Brutsche MH.

Swiss Med Wkly. 2006 Jan 7;136(1-2):13-8.

PMID:
16597094
13.

A Fas agonist induces high levels of apoptosis in haematological malignancies.

Greaney P, Nahimana A, Lagopoulos L, Etter AL, Aubry D, Attinger A, Beltraminelli N, Huni B, Bassi I, Sordat B, Demotz S, Dupuis M, Duchosal MA.

Leuk Res. 2006 Apr;30(4):415-26. Epub 2005 Sep 21.

PMID:
16181674
14.

Molecular basis for the high affinity interaction between the thymic leukemia antigen and the CD8alphaalpha molecule.

Attinger A, Devine L, Wang-Zhu Y, Martin D, Wang JH, Reinherz EL, Kronenberg M, Cheroutre H, Kavathas P.

J Immunol. 2005 Mar 15;174(6):3501-7.

15.

An amyloid-forming segment of beta2-microglobulin suggests a molecular model for the fibril.

Ivanova MI, Sawaya MR, Gingery M, Attinger A, Eisenberg D.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10584-9. Epub 2004 Jul 12.

16.

CD8alphaalpha-mediated survival and differentiation of CD8 memory T cell precursors.

Madakamutil LT, Christen U, Lena CJ, Wang-Zhu Y, Attinger A, Sundarrajan M, Ellmeier W, von Herrath MG, Jensen P, Littman DR, Cheroutre H.

Science. 2004 Apr 23;304(5670):590-3.

17.

Peptide-independent folding and CD8 alpha alpha binding by the nonclassical class I molecule, thymic leukemia antigen.

Weber DA, Attinger A, Kemball CC, Wigal JL, Pohl J, Xiong Y, Reinherz EL, Cheroutre H, Kronenberg M, Jensen PE.

J Immunol. 2002 Nov 15;169(10):5708-14.

18.

The caspase 8 inhibitor c-FLIP(L) modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes.

Lens SM, Kataoka T, Fortner KA, Tinel A, Ferrero I, MacDonald RH, Hahne M, Beermann F, Attinger A, Orbea HA, Budd RC, Tschopp J.

Mol Cell Biol. 2002 Aug;22(15):5419-33.

19.

T cell responses modulated through interaction between CD8alphaalpha and the nonclassical MHC class I molecule, TL.

Leishman AJ, Naidenko OV, Attinger A, Koning F, Lena CJ, Xiong Y, Chang HC, Reinherz E, Kronenberg M, Cheroutre H.

Science. 2001 Nov 30;294(5548):1936-9.

20.

Pairing of Vbeta6 with certain Valpha2 family members prevents T cell deletion by Mtv-7 superantigen.

Aude-Garcia C, Attinger A, Housset D, MacDonald HR, Acha-Orbea H, Marche PN, Jouvin-Marche E.

Mol Immunol. 2000 Nov;37(16):1005-12.

PMID:
11395139
21.

Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.

Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J.

Nat Immunol. 2000 Dec;1(6):489-95.

PMID:
11101870
22.

Lymphoid environment limits superantigen and antigen-induced T cell proliferation at high precursor frequency.

Attinger A, MacDonald HR, Acha-Orbea H.

Eur J Immunol. 2001 Mar;31(3):884-93.

23.
24.

Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo.

Chapuis AG, Paolo Rizzardi G, D'Agostino C, Attinger A, Knabenhans C, Fleury S, Acha-Orbea H, Pantaleo G.

Nat Med. 2000 Jul;6(7):762-8.

PMID:
10888924
25.

Interplays between mouse mammary tumor virus and the cellular and humoral immune response.

Acha-Orbea H, Finke D, Attinger A, Schmid S, Wehrli N, Vacheron S, Xenarios I, Scarpellino L, Toellner KM, MacLennan IC, Luther SA.

Immunol Rev. 1999 Apr;168:287-303. Review.

PMID:
10399081
26.

Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo.

Renno T, Attinger A, Locatelli S, Bakker T, Vacheron S, MacDonald HR.

J Immunol. 1999 Jun 1;162(11):6312-5.

27.

Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis.

Oddo M, Renno T, Attinger A, Bakker T, MacDonald HR, Meylan PR.

J Immunol. 1998 Jun 1;160(11):5448-54.

28.

Expression of B220 on activated T cell blasts precedes apoptosis.

Renno T, Attinger A, Rimoldi D, Hahne M, Tschopp J, MacDonald HR.

Eur J Immunol. 1998 Feb;28(2):540-7.

Supplemental Content

Loading ...
Support Center